Artificial heart manufacturer Carmat declares bankruptcy
Carmat, the French manufacturer of a temporary artificial heart for patients suffering from severe heart failure, announced on Monday, June 30 that it had ceased payments and was requesting the opening of receivership proceedings.
The company, which warned ten days ago that it was at risk of running out of money, will "request the opening of a receivership procedure with the Versailles Economic Affairs Court," according to a press release. Pending the court's decision, "expected in the next few days," Carmat has requested the suspension of its stock price "from Monday, June 30, 2025," before the markets open.
Founded in 2008, the company had stated that it needed to raise at least €3.5 million by June 30, and around €20 million by the end of the year. It had launched a fundraising campaign to ensure its continued operations.
"Despite its continued efforts, the company has not yet managed to secure such additional cash or new financing," said Carmat, which "continues to explore all options that would allow it to continue its activities." The opening of a receivership procedure would, according to the company, constitute "the most appropriate framework to facilitate this continuation."
Carmat assures that "whatever the court's decision," it "will strive to continue to provide support to patients currently benefiting from the Aeson artificial heart ." Carmat's Aeson artificial heart is intended for patients suffering from end-stage heart failure while awaiting a transplant.
To date, 122 patients have been treated with Aeson. The company had voluntarily suspended implantations between the end of 2021 and October 2022 to make improvements to the device following malfunctions that cost the lives of two patients.
La Croıx
